AARD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
19.7M
+30.7%
15.1M
-32.9%
22.5M
+20.1%
18.7M
+5.7%
17.7M
R&D
15.7M
+49.9%
10.5M
-36.9%
16.6M
+15.9%
14.3M
+4.1%
13.7M
SG&A
4.0M
-12.6%
4.6M
-21.5%
5.9M
+33.9%
4.4M
+11.1%
4.0M
Operating Income
-19717000
-30.7%
-15084000
+32.9%
-22464000
-20.1%
-18704000
-5.7%
-17703000
EBITDA
-19707000
-30.7%
-15073000
+32.9%
-22453000
-20.1%
-18694000
-5.7%
-17693000
Net Income
-19186000
-33.4%
-14387000
+33.4%
-21588000
-22.7%
-17598000
-7.9%
-16316000
EPS (Basic)
$-0.88
-33.3%
$-0.66
+33.3%
$-0.99
-23.7%
$-0.80
-6.7%
$-0.75
EPS (Diluted)
$-0.88
-33.3%
$-0.66
+33.3%
$-0.99
-23.7%
$-0.80
-6.7%
$-0.75
Shares (Diluted)
21.9M
+0.2%
21.8M
+0.1%
21.8M
-0.4%
21.9M
+0.9%
21.7M
Aardvark Therapeutics (AARD) — Financials